Skip to main content
Literatur
1.
Zurück zum Zitat Otrock ZK, Azar ST, Shamseddeen WA, Habr D, Inati A, Koussa S et al (2006) Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial. Ann Hematol 85(9):605–609CrossRefPubMed Otrock ZK, Azar ST, Shamseddeen WA, Habr D, Inati A, Koussa S et al (2006) Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial. Ann Hematol 85(9):605–609CrossRefPubMed
2.
Zurück zum Zitat Perifanis V, Vyzantiadis T, Tziomalos K, Vakalopoulou S, Garipidou V, Athanassiou-Metaxa M et al (2007) Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia. Ann Hematol 86(1):23–30CrossRefPubMed Perifanis V, Vyzantiadis T, Tziomalos K, Vakalopoulou S, Garipidou V, Athanassiou-Metaxa M et al (2007) Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia. Ann Hematol 86(1):23–30CrossRefPubMed
3.
Zurück zum Zitat Voskaridou E, Christoulas D, Konstantinidou M, Tsiftsakis E, Alexakos P, Terpos E (2008) Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial. Haematologica 93(10):1588–1590CrossRefPubMed Voskaridou E, Christoulas D, Konstantinidou M, Tsiftsakis E, Alexakos P, Terpos E (2008) Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial. Haematologica 93(10):1588–1590CrossRefPubMed
4.
Zurück zum Zitat Naithani R, Seth T, Tandon N, Chandra J, Pati H, Saxena R et al (2017) Fractures and low bone mineral density in patients with beta thalassemia major. Indian J Hematol Blood Transfus. doi:10.1007/s12288-017-0820-1 Naithani R, Seth T, Tandon N, Chandra J, Pati H, Saxena R et al (2017) Fractures and low bone mineral density in patients with beta thalassemia major. Indian J Hematol Blood Transfus. doi:10.​1007/​s12288-017-0820-1
5.
Zurück zum Zitat Maalouf NM, Heller HJ, Odvina CV, Kim PJ, Sakhaee K (2006) Bisphosphonate induced hypocalcaemia: report of 3 cases and review of literature. Endocr Pract 12:48–53CrossRefPubMed Maalouf NM, Heller HJ, Odvina CV, Kim PJ, Sakhaee K (2006) Bisphosphonate induced hypocalcaemia: report of 3 cases and review of literature. Endocr Pract 12:48–53CrossRefPubMed
Metadaten
Titel
Safety of Zoledronic Acid in Patients with Thalassemia Associated Low Bone Mineral Density
verfasst von
Rahul Naithani
Tulika Seth
Nikhil Tandon
Jagdish Chandra
H. Pati
V. P. Choudhry
Publikationsdatum
09.08.2017
Verlag
Springer India
Erschienen in
Indian Journal of Hematology and Blood Transfusion / Ausgabe 2/2018
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-017-0858-0

Weitere Artikel der Ausgabe 2/2018

Indian Journal of Hematology and Blood Transfusion 2/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.